Juan Frias
Endocrinology, Diabetes & Metabolism · San Diego, CANPI 1134437601
Payments from drug & device makers
Across 4,441 payments — averaging $3181.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$6.8M
- Sanofi US Services Inc.$2.1M
- Novo Nordisk AS$1.6M
- Sanofi-aventis U.S. LLC$833K
- Pfizer$738K
- Boehringer Ingelheim$423K
- plus $1.6M from 27 others
Across 101 payments — averaging $8163.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$713K
- Eli Lilly$75K
- Sanofi-aventis U.S. LLC$19K
- Pfizer$10K
- Regeneron$4K
- Sanofi US Services Inc.$3K
- plus $2K from 2 others
What the payments were for
- Consulting fees$371,41826%
- Speaking & faculty fees$755,16952%
- Travel & lodging$293,82720%
- Food & beverage$16,9541%
- Education$2,2220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 294 | $6,759,773 |
| Sanofi US Services Inc. | 134 | $2,080,447 |
| Novo Nordisk AS | 2,692 | $1,649,639 |
| Sanofi-aventis U.S. LLC | 337 | $832,873 |
| Pfizer | 102 | $738,179 |
| Boehringer Ingelheim | 16 | $423,338 |
| Novartis | 3 | $337,354 |
| AbbVie(2 entities) | 48 | $278,686 |
| Intercept Pharmaceuticals, Inc. | 52 | $221,078 |
| Lilly USA, LLC | 316 | $220,202 |
| Merck | 166 | $154,323 |
| Modernatx, Inc. | 75 | $105,578 |
| Novo Nordisk | 77 | $74,163 |
| Lifescan, Inc. | 48 | $66,785 |
| Janssen Research & Development, LLC | 12 | $64,292 |
| Intercept Pharma Europe Ltd. | 8 | $34,907 |
| Echosens North America, Inc. | 9 | $15,895 |
| Astrazeneca UK Limited | 1 | $14,182 |
| Corcept Therapeutics | 10 | $11,698 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11,040 |
| Hikma Pharmaceuticals USA | 9 | $10,326 |
| Kowa Research Institute, Inc. | 1 | $7,500 |
| BD | 4 | $6,186 |
| Dexcom, Inc. | 1 | $2,975 |
| Lexicon Pharmaceuticals, Inc. | 3 | $2,124 |
| Theratechnologies Inc. | 1 | $2,000 |
| Valeritas, Inc. | 1 | $1,800 |
| Regeneron | 8 | $1,625 |
| Eli Lilly Export S.A. Puerto Rico Branch | 1 | $1,200 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 7 | $343 |
| Gilead | 2 | $143 |
| Abbott | 1 | $51 |
| Madrigal Pharmaceuticals | 1 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$521,211
- TOUJEO$188,468
- MOUNJARO$169,398
- LANTUS$93,833
- STEGLATRO$62,178
- Victoza$34,594
- NO PRODUCT DISCUSSED$30,641
- AMARYL$27,785
- APIDRA$27,193
- INJECTABLES/PHARMA$27,193
- ADLYXIN$27,193
- SOTAGLIFLOZIN$22,669
- OneTouch$18,890
- FibroScan$15,895
- Ozempic$13,646
- OT Verio Reflect "One Touch Meter and Strips"$11,624
- Korlym$11,616
- JANUVIA$9,738
- DIABETES - DISEASE$6,829
- TRULICITY$5,600
How this compares
$14,130,745 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Other endocrinology, diabetes & metabolism in San Diego
- Jerrold OlefskySan Diego$26.5M
- Ken FujiokaSan Diego$750K
- Raymond PlodkowskiSan Diego$546K
- Jeremy PettusSan Diego$544K
- Schafer BoederSan Diego$357K
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.